8th Annual Neuroscience Innovation Forum

EG 427 is developing DNA medicines based on non-replicative HSV-1 vectors for prevalent indications.

EG110A is our lead program currently in Ph1b/2a trial in neurogenic detrusor overactivity (NDO) delivering safety and efficacy read-out in this high-value indication(s) in early ’26.

Our HERpes-based Modular Expression System (HERMES) platform is the foundation for a pipeline in multiple highly prevalent indications.

EuMentis Therapeutics is a clinical stage biopharmaceutical company focused on the development and commercialization of novel circuit-selective medicines to treat neurodevelopmental and other central nervous system conditions. EuMentis is planning to initiate a phase 2 clinical trial in autism spectrum disorder with EM-113 and a phase 2 trial in Schizophrenia with its best-in-class PDE10 inhibitor, EM-221 in 2025.

Galimedix is a Phase 2 clinical-stage private company developing novel oral and topical neuroprotective therapies for serious brain and retinal diseases.

Lead program, GAL-101 (eye drops), is in a Phase 2 trial for the treatment of geographic atrophy (GA), a severe form of dry age-related macular degeneration (dAMD). An oral formulation of GAL-101 has successfully completed Phase 1 testing and shown to be safe, well tolerated, and effectively crosses the blood-brain barrier. Target engagement could be shown. Phase 2 trials in Alzheimer’s (oral) and glaucoma (eye drops) are planned. A next-generation compound, GAL-301, is in pre-clinical testing.
Galimedix is looking for crossover financing to progress GAL-101 to clinical proof of concept in Alzheimer´s disease and to advance its earlier-stage programs ahead of a planned US IPO.

Galimedix has signed a licensing and equity deal with Théa Open Innovation for co-development and commercial rights to GAL-101 in ophthalmology, excluding APAC and is pursuing additional regional partnerships.

Recent highlights include the successful completion of the first-in-human study of the oral version of GAL-101, data presented at CTAD, and the ongoing Phase 2 eDREAM trial in GA, with LPI anticipated this year.

Clinical stage company targeting debilitating central nervous system (CNS) disorders characterized by imbalanced neuronal networks. The Company is advancing multiple, well characterized therapeutic product candidates and has selected indications where underlying disease pathology correlates with the candidate’s molecular target(s). Noema currently has four active Phase 2 clinical trials in highly undertreated CNS conditions: Childhood Onset Fluency Disorder (persistent stuttering), Tourette Syndrome, Trigeminal Neuralgia, and seizures in Tuberous Sclerosis Complex. In addition, the Company has also completed preclinical studies with its triple reuptake inhibitor and anticipates initiating clinical development in 2024. Strong financial position following the close of a $112m Series B led by Forbion and Jeito Capital.

Autifony Therapeutics Limited is a clinical stage biotechnology company dedicated to developing new medicines to treat rare genetic CNS disorders by deploying its pioneering ion channel drug discovery platform.

Based on our vision that Artificial Intelligence Powered Theronostic Technology is the next significant innovation in medicine, we are designing proprietary platforms that will objectively provide novel drug discovery, rapid development of genetically engineered neurons, and precise biometric endpoints to accelerate clinical approvals.

We intend to advance SigNAiture, a Patented Deep Learning Powered platform, that objectively measures Neuronal health in synergy of Confocal microscopy, HD-Multielectrode array, Raman Spectroscopy, and Digital PCR.

SigNAiture will support BRAiN platforms, and will be marketed for Licensure to Pharma, Biotech, and Psychedelic partners for their Neuronal research and Drug Discovery programs.

Engrail is a clinical-stage pharmaceutical company with a rich pipeline of precision-targeted neuroscience programs designed to improve the lives of patients with neuropsychiatric and neurodevelopmental diseases.

JCR Pharmaceuticals is a fully integrated Biopharmaceutical company with focus on rare neurological diseases and an established portfolio in neurological diseases. JCR has approximately 1,000 employees and subsidiaries in the US, Europe and Brazil. JCR is the first company who brought a Biologic to regular approval that was designed to cross the blood-brain-barrier for the treatment of a disease with significant neurological sequalae. Partnerships with pharmaceutical companies are at the core of JCR's portfolio acceleration strategy or to make its blood-brain-barrier transport technology available to enable partner's assets to cross the blood-brain barrier.

Magdalena Biosciences, Inc (Magdalena), incorporated in 2023 as a JV between Jaguar Health and Filament Health, has developed a paradigm shifting approach to drug development, reducing the time from project initiation to clinical trial commencement to 12-24 months (vs 4-6 years for small molecules), saving time, money but, more importantly, improving the probability of success through the development of botanical drugs (under FDA Botanical Guidance) with a focus on plants with a medicinal history of use, frequently used for neuropsychiatric indications by traditional psychiatrists. Magdalena has prepared a pipeline of effective, plant-based psychoactive drugs that are safe for daily dosing and can be used on a long-term basis. Taking advantage of the Jaguar Health library of plant candidates for neuropsychiatric indications (based on input from an impressive Scientific Strategy Team of ethnobotanists, physicians and ethnopharmacologists, knowledgeable of the medicinal properties of plants) and the Filament Health botanical drug development capabilities including their success at filing IND applications with a human dossier of safety rather than animal toxicology data consistent with FDA Botanical Guidance, we have raised seed capital and used it to prepare our first IND to be filed in 2025. We have exciting FDG PET scan data from our first drug candidate, MB2500, demonstrating activity in the prefrontal cortex as well as neuronal connectivity and remodeling in addition to preclinical animal data in the MK801 model of cognitive deficit suggesting MB2500 is able to reverse cognitive deficit as well or better than the classic drug for treating dementia, donepezil, as well as additional data from models for anxiety and depression. MB2500 is based on a plant used in natura by traditional healers. Our first indication with MB2500 is a treatment to improve executive dysfunction in ADHD with a follow-on indication of the improvement of cognitive function in schizophrenia.

Neurocentrx is a UK psychiatry biotech developing an abuse-deterrent oral ketamine and companion digital safety app solution for 1st FDA approval of oral ketamine for severe depression across clinical and home treatment settings.

We are seeking ~$20M over 24 months for clinical proof-of-concept in treatment-resistant major depression, with market approval possible within 4 years.

We are biotech entrepreneurs and leading psychiatrists from Kings College London and McLean Hospital in Boston.

We have funding support from the Wellcome Trust and UK Medical Research Council for ongoing trials in secondary indications of bipolar depression and severe anorexia.

Nine Square Therapeutics, founded by ATP and top scientists at UCSF, is developing innovative treatments for neurodegenerative diseases by targeting genetically validated pathways, with a focus on correcting autophagy/mitophagy dysfunction.

ReST Therapeutics is pioneering transformative therapies for patients with significant unmet needs in psychiatry and neurodegeneration.

Our lead program, RST-01, aims to revolutionize PTSD treatment by focusing on early intervention after traumatic events and adopting a patient-centric clinical strategy. RST-01 targets specific NMDA receptor sub-types, which are crucial for alleviating abnormal fear extension and preventing pathological memory consolidation.

Over the past three years, we have developed pre-clinical proof of concept (POC) in collaboration with top international academic experts and institutions. These data, along with our completed IND-enabling studies, position us to initiate a Phase I clinical study in 2025.

Additionally, ReST Therapeutics is expanding its portfolio and intellectual property with three more pre-clinical candidates targeting neuroinflammation-related neurodegenerative diseases.

InflammaSense is revolutionizing mental health clinical trials with cutting-edge inflammation-sensing technology and AI-enabled solutions. Our non-invasive devices deliver real-time inflammation insights, enhancing trial enrichment and reducing costs. Paired with advanced AI models integrated into EMR systems, we identify reliable patients with unparalleled precision. Focused on mental health as our first use case, we're streamlining patient selection and monitoring to accelerate breakthroughs in conditions like PTSD, MDD, and GAD. Most importantly our clinical trial enrichment tools will radically reduce trial costs. 🚀 #MedTech #Innovation #BioelectronicMedicine #AI #MentalHealth #ClinicalTrials

Myrobalan is a private asset-based pharmaceutical company located in Massachusetts. Our strategy focuses on addressing the brain microenvironment to restore neuronal function through highly selective, oral, small-molecule therapies targeting demyelination and neuroinflammation, which are key drivers of many CNS disorders. Our lead program, MRO-001, is a highly selective CSF1R inhibitor aimed at reducing neuroinflammation in ALS and other neurodegenerative diseases, with the first clinical trial set to be initiated in mid-2025. Our second program, MRO-002, is a GPR17 antagonist designed to promote myelin repair across a broad spectrum of neurodegenerative disorders.